This Article Full Text Full Text (PDF) Data Supplements Guidelines and Associated Tools Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                            What's this?

Use of 5--Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary

In 2005, the ASCO Health Services and Prevention Committees and the American Urological Association jointly convened an expert panel to make recommendations regarding the chemoprevention of prostate cancer and recommendations concerning the use of 5--reductase inhibitors (5-ARIs). The guideline¹ published in Journal of Clinical Oncology was developed on the basis of a systematic review by Wilt et al,² which included nine randomized controlled trials reporting prostate cancer period prevalence.

	Clinical Questions

 
In developing the guideline, the panel asked the following clinical questions about existing evidence regarding 5-ARIs and prostate cancer: How do 5-ARIs affect the risk of incident prostate cancer, prostate . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?